New paper (Traeger): Long-Acting Injectable Cabotegravir PrEP in Practice
New paper led by Michael Traeger in JAIDS: Long-Acting Injectable Cabotegravir HIV PrEP Uptake, Adherence, and Persistence in Two Large US Integrated Healthcare Systems. The study used electronic health records from Kaiser Permanente Northern California and Mid-Atlantic States covering adults who received oral or injectable HIV preexposure prophylaxis (PrEP) between December 2021 and June 2024. Among 23,311 PrEP users, 180 (0.8%) received long-acting cabotegravir (CAB-LA), of whom 23.9% had no documented prior PrEP use. CAB-LA users were more often Black (18.9% versus 10.2%) or Hispanic (34.4% versus 23.6%) than oral-PrEP-only users. Of 688 non-lead-in injections, 90.4% arrived within 8 weeks plus 7 days, and persistence was 87.9% at 6 months and 74.9% at 12 months.
